Non-negligible Risk of Failure.

In its SmPC (summaries of product characteristics), Ranbaxy states that there is a non-negligible risk of medical abortion treatment failure, as follows:

The non-negligible risk of failure, which occurs in 4.5 to 7.8% of the cases, makes the follow-up visit mandatory in order to check that abortion is complete.

The patient should be informed that surgical treatment may be required to achieve complete abortion.

Ranbaxy (UK) Limited is the manufacturer of Medabon, the mifepristone/misoprostol combination treatment provided by BPAS to its pills-by-post clients.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

Create a website or blog at WordPress.com

Up ↑

%d bloggers like this: